
Quarterly report 2023-Q1
added 05-10-2023
Syneos Health EPS Ratio 2011-2026 | SYNH
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Syneos Health
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.26 | 1.85 | 1.27 | 0.23 | -1.85 | 2.08 | 2.02 | -0.51 | -0.81 | -1.14 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.26 | -1.85 | 0.54 |
Quarterly EPS Ratio Syneos Health
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.7 | - | - | - | 0.45 | - | 0.76 | 0.4 | 0.37 | - | 0.61 | 0.04 | 0.32 | 0.88 | 0.57 | 0.11 | -0.29 | 0.44 | -0.1 | 0.13 | -0.24 | -0.14 | -1.7 | 0.06 | 0.39 | 0.7 | 0.5 | 0.56 | 0.32 | 0.55 | 0.67 | 0.4 | 0.41 | -0.92 | 0.24 | 0.29 | -0.03 | -0.25 | -0.02 | -0.21 | -0.32 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.88 | -1.7 | 0.146 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Diagnostics research industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-2.06 | - | -6.23 % | $ 30.6 M | ||
|
Accelerate Diagnostics
AXDX
|
-0.14 | - | -61.36 % | $ 2.46 M | ||
|
Agilent Technologies
A
|
3.98 | $ 115.55 | 3.81 % | $ 35.1 B | ||
|
CareDx, Inc
CDNA
|
-0.4 | $ 20.81 | 0.05 % | $ 1.11 B | ||
|
Co-Diagnostics
CODX
|
-35.2 | $ 1.55 | 1.31 % | $ 2.06 M | ||
|
Castle Biosciences
CSTL
|
0.66 | $ 24.49 | 1.03 % | $ 680 M | ||
|
Akumin
AKU
|
-1.75 | - | -17.87 % | $ 25.9 M | ||
|
Biocept
BIOC
|
-1.89 | - | -13.05 % | $ 7.29 M | ||
|
Fulgent Genetics
FLGT
|
-1.41 | $ 15.19 | 2.64 % | $ 459 M | ||
|
Aspira Women's Health
AWH
|
-0.37 | - | -6.19 % | $ 10.5 M | ||
|
Chembio Diagnostics
CEMI
|
-0.72 | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
4.3 | - | - | $ 9.42 M | ||
|
Heska Corporation
HSKA
|
-1.92 | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-24.3 | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
9.6 | $ 118.33 | 1.86 % | $ 9.76 B | ||
|
Illumina
ILMN
|
-7.69 | $ 126.74 | 5.29 % | $ 20.2 B | ||
|
DermTech
DMTK
|
-3.09 | - | -11.32 % | $ 2.94 M | ||
|
Global Cord Blood Corporation
CO
|
4.12 | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
-0.08 | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.08 | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
-2.91 | $ 166.97 | 1.91 % | $ 8.28 B | ||
|
Lantheus Holdings
LNTH
|
3.46 | $ 84.62 | 4.25 % | $ 5.71 B | ||
|
Enzo Biochem
ENZ
|
-0.51 | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
-1.1 | - | - | $ 19.8 B | ||
|
Medpace Holdings
MEDP
|
15.6 | $ 418.66 | 1.23 % | $ 12.1 B | ||
|
Guardant Health
GH
|
-3.32 | $ 87.08 | 4.4 % | $ 10.9 B | ||
|
Motus GI Holdings
MOTS
|
-15.9 | - | -34.28 % | $ 263 K | ||
|
Koninklijke Philips N.V.
PHG
|
3.67 | $ 26.34 | 2.95 % | $ 20 B | ||
|
Myriad Genetics
MYGN
|
-3.95 | $ 4.75 | 1.5 % | $ 440 M | ||
|
Interpace Biosciences
IDXG
|
5.55 | $ 1.98 | -0.5 % | $ 8.76 M | ||
|
NeoGenomics
NEO
|
-0.84 | $ 9.26 | 3.35 % | $ 1.19 B | ||
|
QIAGEN N.V.
QGEN
|
1.96 | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
-2.16 | $ 2.18 | 0.93 % | $ 5.01 M | ||
|
Laboratory Corporation of America Holdings
LH
|
10.5 | $ 256.8 | -0.13 % | $ 21.4 B | ||
|
National Research Corporation
NRC
|
50 | $ 16.46 | -0.48 % | $ 368 M | ||
|
Celcuity
CELC
|
-3.79 | $ 121.35 | 1.97 % | $ 5.67 B | ||
|
Natera
NTRA
|
-5.57 | $ 206.16 | 5.86 % | $ 20.3 B | ||
|
Neogen Corporation
NEOG
|
-5.03 | $ 9.4 | 4.33 % | $ 2.04 B | ||
|
Invitae Corporation
NVTA
|
-13.2 | - | - | $ 21.2 M | ||
|
Quest Diagnostics Incorporated
DGX
|
8.87 | $ 194.2 | 2.58 % | $ 21.6 B | ||
|
OpGen
OPGN
|
2.44 | - | -16.95 % | $ 1.54 M | ||
|
Organovo Holdings
ONVO
|
-1.7 | - | -2.3 % | $ 19.4 M | ||
|
PerkinElmer
PKI
|
2.07 | - | -0.91 % | $ 14.7 B | ||
|
Exagen
XGN
|
-0.93 | $ 2.9 | 5.07 % | $ 62.5 M | ||
|
Precipio
PRPO
|
-0.23 | $ 30.9 | 3.21 % | $ 49.6 M | ||
|
Burning Rock Biotech Limited
BNR
|
-14.2 | $ 17.0 | 4.68 % | $ 179 M | ||
|
Personalis
PSNL
|
-1.37 | $ 5.52 | 9.52 % | $ 327 M |